// App-Quantinova.ai

: Expression Signature and Prognostic Value of BCL2 Translocation for Diffuse Large B-Cell Lymphoma Patients in China

Researchers

Presenter

  • Yan Qin

Principal Investigators

  • Tian Qiu

  • Xinrui Chen

  • Peng Liu

  • Jianliang Yang

  • Xiaohui He

  • Lin Gui

  • Shengyu Zhou

  • Hongxin Jiang

  • Changgong Zhang

  • Sheng Yang

  • Le Tang

  • Yuankai Shi

Medical Centers

  • Department of Medical Oncology, Suzhou Municipal Hospital, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Solid malignancies

Biomarkers

  • B-cell lymphoma 6

  • Cyclin D3

  • E1A Binding Protein P300

  • CREB-binding protein

  • Enhancer of zeste homolog 2

  • Forkhead Box O1

  • Signal Transducer And Activator Of Transcription 6

  • Immunoglobulin heavy-chain variable region gene

Drug/Treatment

  • EP300

  • EZH2

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved